2016 was a turning point for the bio-based materials and chemicals (BBMC) space as the industry realigned to sustained low oil prices, shifting consumer demand, and emerging regulatory drivers. In our latest report, we highlight the big bets investors placed in 2016 (client registration required). To emphasize these trends, we round-up some of the major announcements throughout the year and summarize them into the three key themes outlined below: Continue reading
Synthetic biology (“synbio”) initially attracted high-profile venture capitalists and corporate partnerships for its products – bio-based chemicals and alternative fuels, for example. Today, synbio companies tools are attracting attention as well – from lab automation like DNA synthesis-as-a-service, to software (i.e. BioCAD and BioLIMS), and new genetic engineering tools (i.e. CRISPR). By integrating machine-learning, robotics, and high-throughput engineering, companies like Ginkgo Bioworks and Zymergen are helping customers dramatically reduce the timeline for developing new molecules in the flavor and fragrance, food ingredient, medical, agricultural, and specialty chemicals markets – a key reason that those two startups each raised more than $100 million in 2016. This podcast highlights Lux’s thoughts on the impact of these tools in and beyond in synbio, and the rapidly developing ecosystem of startups within the space.
To listen to the podcast, click here.
By: Mark Bünger and Victor Oh